ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
2
views
0
references
Top references
cited by
41
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,131
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
PharmGKB summary: fluoropyrimidine pathways.
Author(s):
C Thorn
,
Jeffrey T. Klein
,
Niall M H McLeod
,
Michelle Whirl-Carrillo
,
Sharon Marsh
,
Russ Altman
Publication date:
2011-03-31
Journal:
Pharmacogenetics and Genomics
Keywords:
Antimetabolites, Antineoplastic
,
pharmacokinetics
,
Databases, Factual
,
Deoxycytidine
,
analogs & derivatives
,
Fluorouracil
,
Genome, Human
,
Humans
,
Pharmacogenetics
,
Tegafur
Read this article at
ScienceOpen
Publisher
PMC
Further versions
oa repository (via OAI-PMH doi match)
oa repository (via pmcid lookup)
Powered by
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Acta Materia Medica
Author and article information
Journal
PubMed ID::
20601926
PMC ID::
3098754
DOI::
10.1097/FPC.0b013e32833c6107
ScienceOpen disciplines:
Chemistry
Keywords:
Antimetabolites, Antineoplastic
,
pharmacokinetics
,
Databases, Factual
,
Deoxycytidine
,
analogs & derivatives
,
Fluorouracil
,
Genome, Human
,
Humans
,
Pharmacogenetics
,
Tegafur
Data availability:
ScienceOpen disciplines:
Chemistry
Keywords:
Antimetabolites, Antineoplastic
,
pharmacokinetics
,
Databases, Factual
,
Deoxycytidine
,
analogs & derivatives
,
Fluorouracil
,
Genome, Human
,
Humans
,
Pharmacogenetics
,
Tegafur
Comments
Comment on this article
Sign in to comment
scite_
Similar content
2,131
PharmGKB: vitamin K epoxide reductase complex, subunit 1
Authors:
Exploring the pharmacogenomics knowledge base (PharmGKB) for repositioning breast cancer drugs by leveraging web ontology language (OWL) and cheminformatics approaches
Authors:
Q ZHU
,
C. TAO
,
F SHEN
…
PharmGKB: Gene-specific information tables for CYP3A5
Authors:
See all similar
Cited by
40
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
Authors:
Carin Lunenburg
,
Cathelijne van der Wouden
,
Marga Nijenhuis
…
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
Authors:
A Loganayagam
,
M Arenas-Hernandez
,
R A CORRIGAN
…
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS
Authors:
Dan Rosmarin
,
Claire Palles
,
Alistair T. Pagnamenta
…
See all cited by